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Deficiency of decay-accelerating factor and complement receptor
1-related gene/protein y on murine platelets leads to
complement-dependent clearance by the macrophage phagocytic
receptor CRIg
Abstract
Complement activation on human platelets is known to cause platelet degranulation and activation. To
evaluate how normal platelets escape complement attack in vivo, we studied the fate of murine platelets
deficient in 2 membrane complement regulatory proteins using an adoptive transfer model. We show
here that deficiency of either decay-accelerating factor (DAF) or complement receptor 1-related
gene/protein y (Crry) on murine platelets was inconsequential, whereas DAF and Crry double deficiency
led to rapid clearance of platelets from circulation in a complement- and macrophage-dependent
manner. This finding contrasted with the observation on erythrocytes, where Crry deficiency alone
resulted in complement susceptibility. Quantitative flow cytometry showed DAF and Crry were
expressed at similar levels on platelets, whereas Crry expression was 3 times higher than DAF on
erythrocytes. Antibody blocking or gene ablation of the newly identified complement receptor CRIg, but
not complement receptor 3 (CR3), rescued DAF/Crry-deficient platelets from complement-dependent
elimination. Surprisingly, deficiency of CRIg, CR3, and other known complement receptors failed to
prevent Crry-deficient erythrocytes from complement-mediated clearance. These results show a critical
but redundant role of DAF and Crry in platelet survival and suggest that complement-opsonized
platelets and erythrocytes engage different complement receptors on tissue macrophages in vivo.
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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Deficiency of decay-accelerating factor and complement receptor 1–related
gene/protein y on murine platelets leads to complement-dependent clearance by
the macrophage phagocytic receptor CRIg
David D. Kim,1 Takashi Miwa,1 Yuko Kimura,1 Reto A. Schwendener,2 Menno van Lookeren Campagne,3 and
Wen-Chao Song1
1Institute for Translational Medicine and Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA;
2Institute of Molecular Cancer Research, University of Zu¨rich, Zu¨rich, Switzerland; and 3Department of Immunology, Genentech, South San Francisco, CA
Complement activation on human plate-
lets is known to cause platelet degranula-
tion and activation. To evaluate how nor-
mal platelets escape complement attack
in vivo, we studied the fate of murine
platelets deficient in 2 membrane comple-
ment regulatory proteins using an adop-
tive transfer model. We show here that
deficiency of either decay-accelerating
factor (DAF) or complement receptor 1–
related gene/protein y (Crry) on murine
platelets was inconsequential, whereas
DAF and Crry double deficiency led to
rapid clearance of platelets from circu-
lation in a complement- and macrophage-
dependent manner. This finding con-
trasted with the observation on erythro-
cytes, where Crry deficiency alone
resulted in complement susceptibility.
Quantitative flow cytometry showed DAF
and Crry were expressed at similar levels
on platelets, whereas Crry expression
was 3 times higher than DAF on erythro-
cytes. Antibody blocking or gene ablation
of the newly identified complement recep-
tor CRIg, but not complement receptor 3
(CR3), rescued DAF/Crry-deficient plate-
lets from complement-dependent elimina-
tion. Surprisingly, deficiency of CRIg, CR3,
and other known complement receptors
failed to prevent Crry-deficient erythro-
cytes from complement-mediated clear-
ance. These results show a critical but
redundant role of DAF and Crry in platelet
survival and suggest that complement-
opsonized platelets and erythrocytes en-
gage different complement receptors on
tissue macrophages in vivo. (Blood. 2008;
112:1109-1119)
Introduction
Complement, a part of the innate immune system, is spontaneously
activated by the alternative pathway on susceptible surfaces with
inflammatory and cytolytic consequences.1 To prevent complement
activation, autologous cells express several complement regulatory
proteins on their plasma membrane.2 These proteins, working in
conjunction with fluid-phase complement inhibitors, ensure that comple-
ment activation does not occur on autologous cells under normal
physiologic conditions. In humans, these membrane regulators of
complement include decay-accelerating factor (DAF), membrane cofac-
tor protein (MCP), complement receptor 1 (CR1), and CD59. DAF
inhibits complement activation by preventing the formation and acceler-
ating the decay of C3 and C5 convertases.3 MCP acts as a cofactor for
factor I–mediated degradation of surface-bound C3b and C4b,4 and
CD59 works by inhibiting the assembly of the membrane attack
complex (MAC).5 CR1 regulates complement activation by displaying
both cofactor and decay-accelerating activities.6
Corresponding genes encoding DAF, CD59, and MCP have also
been identified in the rodent.2,7 Interestingly, the mouse has 2 DAF
(daf-1, daf-2)2,7 and 2 CD59 (cd59a, cd59b) genes,2,7 with daf-1 and
cd59a representing the true murine homolog of human DAF and CD59,
respectively.7,8 In addition, the mouse MCP gene, unlike its human
counterpart, is expressed only in the testis.9 However, a rodent-specific
membrane complement regulatory protein referred to as Crry (comple-
ment receptor 1–related gene/protein y) was identified.10 Crry has both
cofactor and decay-accelerating activities and is broadly expressed in the
mouse.11 Given these properties, Crry is considered a functional
homolog of human MCP.7
Platelets and other cells of the hematopoietic system are well
endowed with membrane complement regulatory proteins.12 Indeed,
deficiency of DAF and CD59 on hematopoietic stem cells contributes to
the pathogenesis of paroxysmal nocturnal hematoglobinuria, a disease
characterized by complement-dependent hemolysis and platelet activa-
tion, with anemia and thrombotic attack as the main pathologic
manifestations. Several studies have also shown that complement
anaphylatoxins C3a and C5a and the membrane attack complex
stimulated degranulation and activation of human and animal plate-
lets.13-16 To evaluate the physiologic role of membrane complement
regulators on platelets, we studied the fate of murine platelets that are
deficient in DAF and Crry with the use of an adoptive transfer model.
We describe here that platelets deficient in DAF and Crry, but not DAF
or Crry alone, were rapidly eliminated from the circulation in an
alternative pathway complement- and nonsplenic macrophage-
dependent manner. We further showed that complement-susceptible
platelets were removed by the phagocytic receptor CRIg, whereas
neither CRIg nor any other known complement receptors appeared to be
involved in phagocytosing complement-susceptible erythrocytes. These
results show a critical but redundant role of DAF and Crry in protecting
platelets from complement attack and suggest that complement-
opsonized platelets and erythrocytes engage different complement
receptors on tissue macrophages in vivo.
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Methods
Mice
The generation and source of daf-1/C3-deficient (DAF//C3/), Crry/C3-
deficient (Crry//C3/), daf-1/CD59a-deficient (DAF//CD59a/), daf-
1/Crry/C3-deficient (DAF//Crry//C3/), factor B-deficient (fB/),
and CRIg-deficient (CRIg/) mice were described previously.17-22 JH-
deficient mice (JH/, B-cell deficient)23 were kindly provided by Dr R.
Eisenberg (University of Pennsylvania, Philadelphia). The following mice
were obtained from The Jackson Laboratories (Bar Harbor, ME): C57BL/6
wild-type mice, complement receptor 3 (CR3)–deficient (CD11b/) mice,
C4 knockout (C4/) mice, C5-deficient mice (C5/) harboring a natural
mutation, FcR-chain knockout (FcR/) mice (deficient in both FcRI
and FcRIII),24 and C3 knockout (C3/) mice (backcrossed to C57BL/6
background for 6 generations and further backcrossed in-house for 5 more
generations). Unless specified, male mice aged 8 to 12 weeks were used as
recipients in all transfusion experiments. Mice were maintained under
specific pathogen-free conditions. All animal experiments were approved
by the Institutional Animal Care and Use Committees of the University
of Pennsylvania.
Antibodies
The following antibodies and reagents were purchased from BD PharMingen
(San Diego, CA): purified rat anti–mouse Crry mAb, phycoerythrin (PE)–
conjugated streptavidin, PE-conjugated hamster anti–mouse DAF (CD55) mAb,
allophycocyanin (APC)–conjugated streptavidin, PE-conjugated mouse anti–
mouse IgG1 mAb, purified rat anti–mouse C3a and C5a mAbs, biotinylated rat
anti–mouse C3a and C5a mAbs, purified recombinant mouse C3a and C5a,
horseradish peroxidase (HRP)–conjugated avidin, and PE-conjugated Armenian
hamster anti–mouse CD61 mAb. PE-conjugated mouse anti–rat IgG2a mAb was
purchased from Southern Biotechnology Associates (Birmingham, AL). PE-
conjugated rat anti–mouse integrin IIb3 mAb was from EMFRET Analytics
GmbH & Co KG (Wu¨rzburg, Germany). Rat anti–mouse CD11b mAb (M1/70)
was from BioLegend (San Diego, CA). Mouse anti–rabbit GADPH mAb (6C5)
was from Santa Cruz Biotechnology Inc (Santa Cruz, CA). HRP-conjugated
rabbit anti–mouse IgG fraction of antiserum was from Sigma-Aldrich (St Louis,
MO). The murine CD59a mAb (CD59.3)25 was a gift from Dr Paul Morgan
(Cardiff University, Cardiff, United Kingdom). Goat polyclonal antibodies
against human factor H (cross-reactive with mouse and rat factor H)26 were from
Quidel (San Diego, CA). PE-conjugated donkey anti–goat IgG was from Jackson
ImmunoResearch Laboratories (West Grove, PA). HRP-conjugated rabbit anti–
goat IgG was from Bio-Rad (Hercules, CA). Biotinylated goat anti–mouse C3
antibodies were prepared as described.27 CRIg mAb was generated by immuniz-
ing CRIg-deficient mice with a CRIg-Fc fusion protein prepared as described.21
Clone 14G8 was selected based on its ability to block binding of C3 proteins and
C3-opsonized particles to CRIg (data not shown). Hybridomas for the rat
anti–mouse CR1/2 mAb 7G6 was kindly provided by Dr M. Carroll (Harvard
Medical School, Boston, MA). Hybridoma for the hamster anti–mouse comple-
ment receptor 4 (CR4) mAb N418 was purchased from ATCC (Manassas, VA).
Monoclonal antibodies 7G6 and N418 were produced and purified as
previously described.28,29
Isolation of murine platelets
Mouse blood was collected from the inferior vena cava with a heparinized
syringe and diluted (1:1) with modified Tyrode buffer (137 mM NaCl,
20 mM HEPES, 5.6 mM glucose, 0.1% BSA, 1 mM MgCl2, 2.7 mM KCl,
12 mM NaHCO3, 3.3 mM Na2PO4, pH 7.4).30 Platelet-rich plasma (PRP)
was isolated by centrifugation at 200g for 8 minutes. Platelets were
collected from PRP by centrifugation at 1200g for 8 minutes, washed, and
resuspended with Tyrode buffer. Activation of platelets was assessed by
fluorescence-activated cell sorting (FACS) analysis for activated IIb3
integrin expression.31 All platelet manipulations were performed at room
temperature (RT).
FACS analysis of DAF, Crry, CD59, and factor H on murine
platelets and erythrocytes
Murine platelets were identified by gating platelets in forward and side scattering
and by expression of CD61.32 To detect Crry expression, platelets (107 in 50L)
were stained with purified rat anti–mouse Crry mAb, followed by PE-conjugated
mouse anti–rat IgG2a mAb. To detect DAF expression, platelets were stained
directly with PE-conjugated anti–mouse DAF (CD55) mAb. To detect CD59a,
platelets were stained with a murine CD59a mAb (CD59.3) followed by
PE-conjugated rat anti–mouse IgG1 mAb. To detect factor H expression, platelets
and erythrocytes (107 in 50L) were stained with goat polyclonal anti–human
factor H, followed by PE-conjugated donkey anti–goat IgG. All stainings and
washings were carried out in FACS buffer (0.1% albumin and sodium azide in
phosphate-buffered saline). Incubation with antibody was performed at RT for
1 hour. Samples were analyzed on a FACS Calibur flow cytometer (Becton
Dickinson, Franklin Lakes, NJ). Data were acquired with the CellQuest
software (Becton Dickinson) and analyzed with the FlowJo software (TreeStar,
Ashland, OR).
We determined the number of DAF, Crry, and CD59a molecules expressed
on mouse platelets by FACS using QuantiBRITE beads (Becton Dickinson) as
described previously for erythrocytes.27,33 Briefly, platelets were stained with
PE-labeled primary or secondary mAbs with known antibody/PE molecular
ratios. The number of DAF, Crry, or CD59a molecules per platelet was estimated
based on the platelet mean fluorescence intensity (MFI) and a standard curve of
MFI generated by a set of 4 precalibrated PE-labeled fluorescent beads.27,33
Assessment of platelet half-life and C3 deposition in vivo
To determine the survival of transfused platelets in vivo, isolated platelets
from donor mice were labeled ex vivo with carboxy fluorescein diacetate
succinimidyl ester (CFSE; Invitrogen, Carlsbad, CA) in 1 mL PBS contain-
ing 5 M of CFSE. The labeled platelets were then introduced into various
recipient mice by the tail vein. Blood samples were collected 10 minutes
after platelet infusion in 1 mL of 0.2 M EDTA-PBS and at various time
points thereafter as indicated. Platelets were isolated by centrifugation and
analyzed directly by FACS for CFSE staining, and the percentage of
CFSE-positive platelets was determined at each time point. For analysis of
in vivo C3 deposition on platelets, isolated platelets were stained with
biotinylated goat anti–mouse C3 antibodies, followed by APC-conjugated
streptavidin. C3 deposition on platelets was determined by FACS and
expressed as MFI. Assessment of erythrocyte half-life in vivo was carried
out as previously described.18,19,27
In vitro complement deposition assays
Washed platelets and erythrocytes (107 in 100 L) were incubated with
mouse plasma/serum (at 10%, 20%, 40%, and 80%) in modified Tyrode
buffer at 37°C for 20 or 60 minutes. After incubation, cells were washed
3 times with PBS and stained with biotinylated goat anti–mouse C3 and
APC-conjugated streptavidin. In some experiments they were costained
with PE-conjugated rat anti–mouse integrin IIb3 mAb as an activation
marker. The extent of C3 deposition and level of IIb3 expression on
platelets was determined by FACS.
C3a/C3a-desArg and C5a/C5a-desArg enzyme-linked
immunoabsorbent assay
Washed platelets (107 in 100L) were incubated with 40% wild-type mouse
plasma (in 100 mM EGTA-MgCl2) in modified Tyrode buffer at 37°C for
30 minutes. After incubation, cells were spun down, and the supernatants were
assayed for the levels of C3a/C3a-desArg and C5a/C5a-desArg by sandwich
enzyme-linked immunoabsorbent assay (ELISA). ELISA plates were coated
overnight at 4°C with rat anti–mouse C3a (clone I87-1162) or C5a (clone
I52-I486), which also recognized C3a-desArg and C5a-desArg, respectively.
After blocking with assay diluents (BD PharMingen) at RT for 1 hour, plasma
samples or C3a/C5a standards (150 pg to 300 ng/mL for C3a, 75 pg to
150 ng/mL for C5a in assay diluents) were added to the plates and incubated at
RT for 1 hour. Plates were washed and incubated with biotinylated rat anti–mouse
C3a (clone I87-419) or C5a (clone I52-278) for 1 hour and then developed with
avidin-conjugated HRP.
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Retroviral vector-mediated transgenic expression of Crry
A 1.3-kb mouse Crry cDNA was amplified by reverse transcription–polymerase
chain reaction (PCR) from C57/BL6 mouse spleen cDNAs with 5-CTGCA-
GGTAAAACGTTGTTTGAGAACGGTG-3 and 5-GAATTCCGTGCT-
GGGCTAGTGGT-3 as primers. The cDNAwas cloned into the PCR 2.1 vector
(Invitrogen) and then subcloned at EcoRI sites into MigR1, a bicistronic
retroviral vector carrying a green fluorescence protein marker downstream of
encephalomyocarditis virus internal ribosomal entry site in tandem with the
transgene.34 (MigR1 vector was kindly provided by Dr W.S. Pear, University of
Pennsylvania). Production of Crry-encoding retrovirus and transduction of
mouse bone marrow stem cells were carried as described previously.27
In vivo macrophage depletion
To deplete macrophages, mice were intravenously injected with clodr-
onate-liposomes (2 mg/20 g).35,36 This treatment is known to deplete
splenic, hepatic, and bone marrow macrophages within 24 hours.35,36
Liposome-encapsulated PBS was used as a negative control. After
24 hours of clodronate treatment, more than 90% of the macrophages in
spleen and bone marrow were shown to be eliminated, as indicated by
F4/80 staining by FACS (data not shown). To exclude the possibility
that clodronate-liposomes may affect systemic complement activity,
sera from the treated mice were analyzed using an in vitro zymosan-
induced complement activation assay.27 Neither clodronate-liposomes
nor PBS-liposomes were found to affect systemic complement activity
(data not shown).
Splenectomy
Splenectomy was performed under Avertin anesthesia. An incision was
made on the abdomen over the spleen. The splenic artery was ligated with
the nonabsorbable suture Dermalon (Tyco Healthcare, Norwalk, CT). After
the connective tissues were cut away, the spleen was removed. The incision
was closed with nonabsorbable sutures, and the skin was closed with
7.5-mm MICHEL wound clips (Roboz Surgical Instrument, Gaithersburg,
MD). Mice were used as transfusion recipients 2 weeks after surgery.
In vivo anti-CRIg, CR1/2, CR3, and CR4 treatment
To block CRIg function in vivo, 12 mg/kg of rat anti–mouse CRIg mAb was
injected subcutaneously daily, starting from one day before the transfusion
experiment. To block CR1/2 function in vivo, 200 g of rat anti–mouse
CR1/2 mAb (7G6) was injected intravenously 24 hours before the
transfusion experiment.28 To block CR3 function in vivo, 200 g of rat
anti–mouse CD11b mAb (M1/70) was injected intravenously 2 hours
before the transfusion experiment.37 To block CR4 function in vivo, 500 g
of hamster anti–mouse CR4 mAb (N418) was injected intraperitoneally
24 hours before the transfusion experiment.29
Western blot analysis
Washed platelets and red blood cell (RBC) ghosts were solubilized in 1%
Nonidet P-40. The platelet and RBC proteins (240g total protein/lane) along
with human and mouse serum (0.5L/lane) were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) under reducing condi-
tions and then transferred to a polyvinylidene diflouride membrane (Millipore,
Billerica, MA). Western blot analysis was performed as described previously,38
using polyclonal goat anti–human factor H (1:5000) and a murine GAPDH
(1:200) mAb.
Results
Expression of DAF, Crry, and CD59a on murine platelets
We determined by FACS analysis the expression of DAF, Crry, and
CD59a on wild-type (WT) mouse platelets. As negative controls, we
used platelets from DAF/C3/, Crry//C3/, and DAF//
CD59a/ mice. Previous work has shown that Crry gene knockout
caused embryonic lethality, and viable Crry/ mice could only be
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Figure 1. Expression of DAF, Crry, and CD59 on murine
platelets. FACS analysis of DAF (A) and Crry (B) on
wild-type mouse platelets. Platelets from DAF//C3/ and
Crry//C3/micewereusedasnegativecontrols. (C)FACS
analysis of CD59a levels on WT (614 32 molecules/cell)
and various knockout mouse platelets. Platelets from DAF//
CD59a/mice were used as negative controls. (D) Compari-
son of the number of DAF and Crry molecules on WT,
DAF//C3/, and Crry//C3/ mouse platelets. WT and
Crry//C3/ mouse platelets expressed 286 ( 98)
and 282 ( 57) DAF molecules/platelet, respectively. WT
and DAF//C3/ mouse platelets expressed 294 ( 86)
and 274 ( 71) Crry molecules/platelet, respectively. Error
bars represent SEM.
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obtained on a C3/ background.17 As shown in Figure 1A,B, abundant
expression of DAF and Crry was detected on WT mouse platelets, but
both proteins were absent from DAF/C3/ or Crry//C3/ mouse
platelets, respectively. Similarly, high-level expression of CD59a was
detected on WT but not on DAF//CD59a/ mouse platelets (Figure
1C). Furthermore, deficiency of DAF, Crry, or both on platelets did not
cause a compensatory change in CD59a expression (Figure 1C). Using
quantitative FACS analysis, we estimated that the number of DAF, Crry,
and CD59 expressed on mouse platelets was 286 plus or minus 98, 294
plus or minus 86, and 614 plus or minus 32 molecules/platelet,
respectively. No reciprocal compensatory change in the expression of
DAF and Crry on Crry//C3/ or DAF/C3/ platelets was noted
(Figure 1D).
DAF/Crry-deficient but not DAF-deficient or Crry-deficient
mouse platelets had a shortened half-life in vivo
To determine the respective roles of DAF and Crry in protecting
platelets from complement attack in vivo, we transferred CFSE-
labeled WT, DAF-deficient (from DAF//C3/ mice), Crry-
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Figure 2. Complement susceptibility of WT and mu-
tant mouse platelets. (A) Normal survival of transfused
WT (f; n  4), Crry//C3/ (E; n  5), and DAF//
C3/ (F; n  4) mouse platelets in WT recipients; n
refers to the number of recipient mice. Platelets were
pooled from 2 to 3 donor mice. (B) Accelerated elimina-
tion of DAF//Crry//C3/ (; n  4) but not DAF//
CD59a/ (; n  4) mouse platelets compared with
WT (f; n  3) mouse platelets. In panels A and B,
platelets were pooled from 2 to 3 donor mice. Blood
samples were taken at 10 minutes after labeled platelets
were intravenously infused, and the percentage of la-
beled platelets at this time point was taken as 100% for
later reference. (C) FACS analysis of C3 deposition on
donor platelets from panel A (WT, Crry//C3/, DAF//
C3/) and panel B (DAF//Crry//C3/). MFI indi-
cates mean fluorescence intensity. C3 deposition on
DAF//Crry//C3/ platelets at 12 hours and 24 hours
were significantly higher than C3 deposition on any other
platelets (P 	 .05, Student t test). (D) FACS analysis of
C3 deposition on WT, DAF//C3/, Crry//C3/, and
DAF//Crry//C3/ mouse platelets in vitro. Washed
platelets were incubated with mouse serum (20% diluted
in Tyrode buffer) at 37°C for 30 minutes. Similar results
were obtained with 40% serum. Three mice were used in
each group. Triplicate assays for each mouse were
performed. (E) FACS analysis of activated IIb3 inte-
grin on CFSE-labeled DAF//Crry//C3/ platelets
2 hours after transfer into WT recipients. (F) FACS
analysis of activated IIb3 integrin on WT and DAF//
Crry//C3/ mouse platelets after in vitro incubation
(30 minutes, 37°C) with 10% or 40% WT mouse plasma
(in 10 mM EGTA-MgCl2). Numbers on plots are percent-
ages of cells in gates. (G) ELISA analysis of C3a/C3a-
desArg concentration in mouse plasma after in vitro
incubation with WT or DAF//Crry//C3/ mouse
platelets. Intact plasma (not incubated) and plasma
incubated in the absence of added platelets were used
as controls. All plasma samples, including controls, were
diluted to 40% in 10 mM EGTA-MgCl2 before assay.
(H) ELISA analysis of C5a/C5a-desArg concentration in
mouse plasma after in vitro incubation. Experimental
conditions were the same as panel G. Error bars repre-
sent mean ( SEM) of triplicate assays. *P 	 .001,
**P 	 .05, Student t test.
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deficient (from Crry//C3/ mice), or DAF/Crry-deficient (from
DAF//Crry//C3/ mice) platelets into WT recipients and
monitored their fate. We detected no significant effect on platelet
half-life by either DAF or Crry deficiency (Figure 2A). However,
platelets deficient in both DAF and Crry were more rapidly
eliminated from the circulation (Figure 2B). In contrast to DAF/
Crry double deficiency, DAF/CD59 double deficiency had no
consequence on platelet survival (Figure 2B). Correspondingly, we
detected significant C3 deposition only on DAF/Crry-deficient
platelets in vivo or when they were incubated with normal mouse
serum in vitro (Figure 2C,D). These results suggested that DAF and
Crry played a critical but redundant role in protecting platelets from
complement attack. Interestingly, we detected no surface expres-
sion of activated IIb3 integrin or up-regulation of P-selectin,
markers of platelet activation, on DAF/Crry-deficient platelets
either in vivo or in vitro (Figure 2E,F; unpublished data), suggest-
ing that C3-opsonized platelets did not display an activated
phenotype. Consistent with surface deposition of C3 on DAF/Crry-
deficient platelets, we detected significantly increased levels of
C3a/C3a-desArg and C5a/C5a-desArg in the plasma sample incu-
bated with DAF/Crry-deficient platelets (Figure 2G,H). We did not
detect any increase in plasma C3a/C3a-desArg and C5a/C5a-
desArg in vivo after platelet infusion (data not shown), presumably
because of rapid pharmacokinetic and/or volume of distribution
effect. Addition of CD59a- and CD59b-blocking antibodies to in
vitro assays also failed to up-regulate P-selectin or to induce
activated IIb3 integrin (data not shown), indicating that lack of
platelet activation was not due to CD59-dependent inhibition of
MAC formation on the platelet surface.
Transgenic expression of Crry rescued DAF/Crry-deficient
platelets in vivo
To confirm that the shortened half-life of DAF/Crry-deficient
platelets in vivo was indeed due to membrane complement
regulator deficiency, we restored Crry expression to the hematopoi-
etic cells of DAF//Crry//C3/ mice by retroviral vector-
mediated Crry gene transduction of bone marrow stem cells.
Approximately 25% of the platelets from the transgenic mice
became Crry-positive (data not shown) and expressed 6228 ( 290)
Crry molecules/platelet. Platelets were harvested from these mice,
labeled with CFSE, and then transfused into WT mouse recipients.
As shown in Figure 3A, the transfused platelets were CFSE
positive (population X and Y) and distinguishable from the
endogenous platelets (population Z). We observed that Crry-
positive platelets (population Y) survived normally, whereas most
Crry transgene-negative platelets (population X) disappeared from
the circulation during a 20-hour period (Figure 3A,B). Thus,
transgenic expression of Crry on DAF/Crry-deficient platelets
rescued them from accelerated elimination, further showing a
direct causal relation between shortened platelet half-life and
membrane complement regulator deficiency.
Elimination of DAF/Crry-deficient platelets required alternative
pathway complement
To directly test the hypothesis that DAF/Crry-deficient platelets
were eliminated by a complement-dependent mechanism, we
monitored the survival of transfused DAF/Crry-deficient platelets
in C3/, C4/, fB/, C5/, JH/, and FcR/ mice. C3/
mice lacked overall complement activity, whereas C4/, fB/,
and C5/ mice lacked the classical, alternative, or the terminal
pathway of complement, respectively. JH/ mice were deficient in
B cells and produced no antibodies, and FcR/ mice lacked FcRI
and FcRIII.24 We found that C3 and fB deficiency but not C4, C5,
JH, or FcR deficiency rescued DAF/Crry-deficient platelets from
accelerated elimination (Figure 4A). Thus, abnormal clearance of
mutant mouse platelets from the circulation required participation
of the alternative, but not the classical or terminal complement
pathway, and it did not involve FcR-mediated phagocytosis. In
support of this conclusion, we found that C3 opsonization of
DAF/Crry-deficient platelets in vitro was dependent on fB but not
on C4 (Figure 4B).
DAF/Crry-deficient platelets were phagocytosed by nonsplenic
macrophages
To determine whether DAF/Crry-deficient platelets were phagocytosed
by macrophages after complement opsonization, we depleted macro-
phages from WT recipients by clodronate-liposome treatment. As
previously reported,35,36 macrophages in the spleen and bone marrow
were shown to be largely (
 90%) depleted at 24 hours after intrave-
nous injection of clodronate-liposomes (data not shown). Importantly,
we found that DAF/Crry-deficient platelets were protected from acceler-
ated elimination when transfused into clodronate-liposome–treated
mice, displaying a half-life that was indistinguishable from platelets
transfused into C3/ mice (Figure 4C). In contrast, mice treated with
control liposomes rapidly eliminated DAF/Crry-deficient platelets as
usual (Figure 4C). This result strongly suggested that DAF/Crry-
deficient platelets were phagocytosed by macrophages. To examine
whether splenic or other tissue macrophages such as liver Kupffer cells
were responsible, we compared the survival of DAF/Crry-deficient
platelets transfused into splenectomized WT mice or sham-operated
controls. Figure 4D shows that splenectomy did not prevent the rapid
elimination of DAF/Crry-deficient platelets. No difference in clearance
kinetics was observed between platelets transfused into splenectomized
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Figure 3. Rescue of DAF//Crry//C3/ mouse
platelets by retroviral transgenic expression of Crry.
(A) Tracking by FACS of the survival of nontransgenic
(population X) and Crry-transgenic (population Y) DAF/
/Crry//C3/ platelets in WT recipients. Donor plate-
lets were labeled with CFSE and were distinguishable
from endogenous WT platelets (population Z). (B) Plot of
elimination kinetics of populations X and Y platelets in
panel A. The percentage of platelets remaining at each
time point was normalized to the percentage of platelets
remaining at 10 minutes after transfusion.
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Figure 4. Role of complement, macrophage, and complement receptors in the elimination of DAF/Crry-deficient platelets. (A) DAF//Crry//C3/ platelets had
accelerated elimination in C4/, C5/, JH/, and FcR/ mice but not in fB/ and C3/ mice (n  3 for each type of recipients). (B) FACS analysis of C3 deposition on
DAF//Crry//C3/ mouse platelets (n  3) after in vitro incubation with 20% WT, C4/, fB/, or C3/ mouse serum in Tyrode buffer, 5 mM MgCl2-EGTA, or 10 mM
EDTA. Similar results were obtained with 40% serum. Sera were pooled from 3 to 4 mice of each genotype. Error bars represent means  SEM of triplicate assays. (C)
Treatment of recipient mice with clodronate-liposomes (f; n  4) but not PBS-liposomes (; n  4, negative control) prevented accelerated elimination of DAF//Crry//
C3/ platelets. C3/ mice (F; n  4) were used as control recipients for the rescue experiment. (D) Splenectomy (SPX) did not prevent DAF//Crry//C3/ platelets from
accelerated elimination. DAF//Crry//C3/ platelets transfused into splenectomized WT recipients (f; n  3) had similar half-life to those transfused into sham-operated
WT mice (; n  3), and both had accelerated elimination compared with WT platelets transfused into splenectomized WT recipients (F; n  3). (E) Blockade of CR3 in WT
mice by anti-CR3 (M1/70) (f; n  3) or CR3 gene knockout (Œ; n  3) did not rescue DAF//Crry//C3/ platelets from accelerated elimination. Blockade of CR4 in CR3/
mice by anti-CR4 (N418) (E; n  2) and blockade of CR1/2 in WT mice by anti–CR1/2 (7G6) (; n  3) also did not prevent the elimination. WT (; n  3) and C3/ (F; n  3)
were used as control recipients. (F) Blockade of CRIg in WT mice by anti-CRIg (14G8.2) (F; n  3) or CRIg gene knockout (f; n  3) prevented DAF//Crry//C3/
platelets from accelerated elimination. WT (; n  3) and C3/ (E; n  3) were used as control recipients.
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and sham-operated mice, suggesting that they were primarily removed
by nonsplenic macrophages.
Phagocytosis of DAF/Crry-deficient platelets was mediated by
CRIg
Both CR3 and the recently discovered complement receptor
CRIg are capable of mediating phagocytosis of complement-
opsonized particles, and pathogens and both are expressed on
tissue macrophages.21,39 To determine whether phagocytosis of
DAF/Crry-deficient platelets was mediated by these receptors,
we transfused DAF/Crry-deficient platelets into mice that
lacked functional CR3 or CRIg as a result of antibody blocking
or gene deletion.21,22,40,41 As shown in Figure 4E, antibody
blocking of CR3 in WT mice or genetic disruption of CR3
(CD11b gene knockout) had no effect on the accelerated
elimination of DAF/Crry-deficient platelets. Moreover, anti-
body blocking of CR1/2 in WT mice or CR4 in CR3/ mice did
not rescue the transfused DAF/Crry-deficient platelets. In
contrast, antibody blocking of CRIg in WT mice or genetic
inactivation of the CRIg gene completely prevented DAF/Crry-
deficient platelets from rapid elimination (Figure 4F). Thus,
macrophage CRIg but not CR3, CR1/2, or CR4 mediated
phagocytosis of DAF/Crry-deficient platelets.
Complement-opsonized platelets and erythrocytes engage
different macrophage receptors
We previously showed that Crry- and DAF/Crry-deficient
mouse erythrocytes were susceptible to complement attack in
vivo.18,19 To extend the current study and establish the roles of
macrophages and CRIg in the clearance of regulator-deficient
erythrocytes, we treated recipient mice with clodronate-
liposomes or performed splenectomy before erythrocyte transfu-
sion. Figure 5A,B shows that, similar to regulator-deficient
platelets, the elimination of DAF/Crry-deficient erythrocytes
was also critically dependent on nonsplenic macrophages.
Unexpectedly, however, we found that neither CR3 nor CRIg
deficiency protected DAF/Crry-deficient erythrocytes from
complement-mediated clearance (Figure 5C). Furthermore, anti-
body blocking of CRIg, CR4, and CR1/2 in CR3/ mice also
failed to rescue DAF/Crry-deficient erythrocytes from acceler-
ated elimination (Figure 5D), suggesting that the failure to
prevent complement-dependent phagocytosis of the mutant
mouse erythrocytes was not due to redundancy between any of
the known complement receptors.
DAF/Crry-deficient platelets were more susceptible to
alternative pathway complement attack than DAF/Crry-deficient
erythrocytes
Although both DAF/Crry-deficient platelets and erythrocytes were
susceptible to complement-dependent elimination in vivo, we
found that DAF/Crry-deficient platelets were significantly more
prone to C3 opsonization than DAF/Crry-deficient erythrocytes
when exposed to wild-type mouse serum. As shown in Figure
6A-C, after 20 minutes of incubation in 10% to 40% wild-type
mouse plasma, DAF/Crry-deficient platelets, but not DAF/Crry-
deficient erythrocytes, were heavily opsonized with C3. In contrast,
notable C3 deposition on DAF/Crry-deficient erythrocytes was
observed only after 60 minutes of incubation in 40% or 80%
plasma (Figure 6D-F).
Apart from DAF and Crry, the plasma protein factor H also
confers host cell protection from alternative pathway complement
attack,42 and previous work from others has suggested the presence
of a membrane form of factor H on murine platelets.26 We
wondered wether a similar membrane-associated form of factor H
might be present on the mouse erythrocytes and whether different
levels of such a protein might have accounted for the differential
sensitivity of DAF/Crry-deficient platelets and erythrocytes to
alternative pathway complement. Although we detected by FACS
analysis cross reactivity with anti–human factor H antibodies both
on platelet and erythrocyte surfaces (Figure 7A,B), subsequent
Western blot analysis only confirmed the presence of factor H on
the mouse platelets (Figure 7C). Thus, membrane-associated factor
H was an unlikely determinant for the observed differential
sensitivity of DAF/Crry-deficient platelets and erythrocytes to
alternative pathway complement.
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Figure 5. Role of macrophage and complement recep-
tors in the elimination of DAF//Crry//C3/ eryth-
rocytes. (A) Treatment of recipient mice with clodronate-
liposomes (f; n  4) but not PBS-liposomes (; n  4,
negative control) prevented accelerated elimination of
DAF//Crry//C3/ erythrocytes. C3/ mice (F;
n  4) were used as control recipients. (B) Splenectomy
(SPX) did not prevent DAF//Crry//C3/ erythro-
cytes from accelerated elimination. DAF//Crry//
C3/ erythrocytes transfused into splenectomized WT
recipients (f; n  3) had similar half-life to those trans-
fused into sham-operated WT mice (; n  3), and both
were rapidly eliminated. WT erythrocytes transfused into
splenectomized WT recipients (F; n  3) remained stable.
(C) DAF//Crry//C3/ mouse erythrocytes were not
rescued in CRIg/ (; n  4) or CR3/ (Œ; n  3)
mice. WT (f; n  3) and C3/ (F; n  3) mice were
used as control recipients. (D) Neither blockade of CRIg
by antibody (16G8.2) in CR3/ mice (Œ; n  2) nor
blockade of CRIg, CR1/2, CR4 by antibody (16G8.2),
(7G6), and (N418) all in CR3/ mice (‚; n  3) did not
rescue DAF//Crry//C3/ erythrocytes. WT (f; n  2)
and C3/ (F; n  2) mice were used as control
recipients. Error bars represent SD.
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Discussion
We found here that DAF and Crry played an equally important but
redundant role in protecting murine platelets from alternative
pathway complement-mediated elimination. This observation con-
trasted with previous findings that Crry played a more critical role
than DAF on mouse erythrocytes.18,19 This discrepancy could be
explained by the relative levels of DAF and Crry on platelets and
erythrocytes. We showed in this study that DAF and Crry were
expressed at a similar level on the platelets, whereas Crry level was
3 times higher than DAF on erythrocytes.27 Considering the size
differences between the 2 cell types, the relative density of DAF
and Crry on the platelet surface was calculated to be much higher
than that on erythrocytes. Overall, these data supported the
conclusion that when expressed at a sufficiently high level, either
DAF or Crry is capable of controlling alternative pathway comple-
ment activation on the cell surface.
Previous studies with human and animal platelets have shown
that deposition of the membrane attack complex or stimulation
with C3a/C5a led to platelet degranulation and activation.13-16 It
was notable that, despite increased C3a and C5a release and
abundant surface C3 deposition on DAF/Crry-deficient platelets,
we observed no P-selectin or activated IIb3 integrin expression
on these platelets, suggesting that they did not have an activated
phenotype. Neutralization of CD59a and CD59b on DAF/Crry-
deficient platelets with blocking mAbs during in vitro complement
activation assays moderately increased surface MAC staining (data
not shown) but likewise did not induce P-selectin or activated
IIb3 integrin expression. It is possible that murine platelets are
less sensitive than human platelets to MAC-induced degranulation
and activation. Alternatively, a higher number of MAC molecules
on the platelet surface are needed to cause platelet activation, a
requirement that could not be met in vivo because of CD59 activity
or in vitro because of low terminal complement activity in
conventionally prepared mouse plasma. Separately, lack of C3a/C5a-
stimulated platelet activation may be explained by the absence of
C3a and C5a receptors on murine platelets. Consistent with earlier
reports in human platelets,43,44 we detected no C5aR or C3aR
expression on mouse platelets by FACS (data not shown).
Through the use of gene knockout mice, we established that the
accelerated elimination of DAF/Crry-deficient platelets was depen-
dent on the alternative but not the classical pathway of comple-
ment. We also showed that the terminal complement system and the
FcR pathway were not involved. These results pointed to comple-
ment receptor (CR)–mediated phagocytosis as a potential mecha-
nism for their removal from the circulation. Indeed, we detected
abundant C3 opsonization of DAF/Crry-deficient platelets and
showed that macrophage depletion rescued DAF/Crry-deficient
platelets from accelerated elimination. Macrophages from the
spleen and liver (Kupffer cells) are known to express several
complement receptors, including CR345 and the recently identified
CRIg.21 Notably, we found that splenectomy had no effect on the
accelerated elimination of DAF/Crry-deficient platelets and eryth-
rocytes, suggesting that the regulator-deficient cells were phagocy-
tosed primarily by nonsplenic macrophages, most likely liver
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Kupffer cells. This finding seemed to contradict the previous
observation that CFSE-labeled Crry-deficient erythrocytes accumu-
lated in the spleen but not in the liver of the recipient mice.19 It is
possible that both splenic macrophages and Kupffer cells were
involved, but the relatively small size of the spleen makes its
contribution to the total phagocytic activity in vivo negligible.
Alternatively, but not mutually exclusively, Kupffer cells may
process and degrade the ingested erythrocytes at a higher rate and
more efficiently, explaining why we detected no CFSE label in the
recipient mouse liver in the earlier experiment.19
With the use of blocking antibodies and gene knockout mice,
we identified the recently discovered complement receptor CRIg as
the critical macrophage phagocytic receptor for DAF/Crry-
deficient platelets. Thus, CRIg served as a complement receptor
not only for complement-opsonized pathogens21 but also for
complement-opsonized autologous cells. Given the propensity of
apoptotic cells to trigger complement activation and C3 ligand
deposition, it will be of interest to determine whether CRIg might
be involved in the processing of apoptotic cells, thereby potentially
playing a role in preventing systemic autoimmunity. The finding
that functional deficiencies of CRIg, CR1/2, CR3, and CR4 failed
to prevent complement-dependent elimination of DAF/Crry-
deficient erythrocytes was intriguing and raised the possibility of
additional complement receptor(s) yet to be identified. It is also
conceivable that DAF/Crry-deficient erythrocytes were removed
by a complement-dependent but CR-independent mechanism. For
example, complement attack may have exposed cryptic recognition
molecules on the “stressed” erythrocytes, leading to their acceler-
ated elimination through non–CR-dependent mechanisms.
Why do complement-opsonized platelets and erythrocytes en-
gage different phagocytic receptors in vivo? One obvious differ-
ence between platelets and erythrocytes is their size. The calculated
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volume of an erythrocyte is 6.5 times that of a platelet (mean
erythrocyte volume, 45.7 fL; mean platelet volume, 7.01 fL).46
However, previous studies have shown that CRIg is capable of
mediating the phagocytosis of complement-opsonized sheep eryth-
rocytes in vitro,21 suggesting that cell size is not a critical
determinant. A more likely explanation is that the amount and
nature of C3 ligand(s) deposited on DAF/Cry-deficient platelets
and erythrocytes were considerably different. Indeed, we found
that DAF/Crry-deficient platelets were much more susceptible to
C3 opsonization than were DAF/Crry-deficient erythrocytes in
vivo and in vitro, and previous experiments have shown that
dimeric murine CRIg has a relatively low affinity for monomeric
C3b/iC3b.21,22 We also probed the nature of C3 fragments deposited
on the mutant platelets and erythrocytes using 2 anti–C3 antibod-
ies, mAb 2/11 (recognizes C3b, iC3b, C3c) and mAb 2/16
(recognizes C3, iC3b, C3c).47 We found that mAb 2/11 and mAb
2/16 detected similar levels of C3 deposition on platelets but that
mAb 2/11 detected more C3 staining than mAb 2/16 on erythro-
cytes (unpublished data). These results indicated that the composi-
tion of the C3 ligands deposited on the 2 cell types was indeed
different. The mechanism underlying differential complement
opsonization of the 2 cell types is not clear. MCP, another important
membrane C3 complement regulator, is known to be expressed
only in the mouse testis9 and is therefore unlikely to be responsible
for the differential sensitivity. We also explored constitutive
association of fH, a fluid-phase C3 regulator,42 with mouse platelets
and erythrocytes and excluded its level as a possible contributor.
Nevertheless, it is possible that fluid-phase fH may have a higher
affinity for C3b deposited on erythrocytes than that on platelets
because of differences in cell surface constituents (eg, sialic acid)
that favor fH-host cell interaction during complement activation.48,49
In summary, we have established a critical but redundant role of
DAF and Crry in protecting murine platelets from alternative
pathway complement attack. We further showed that phagocytosis
of complement-opsonized platelets was mediated by CRIg on
nonsplenic macrophages, whereas neither CRIg nor CR3 were
essential for the clearance of complement-susceptible erythrocytes.
These results suggest that the level of DAF or Crry expression on a
given cell type is a critical determinant for its overall activity and
relevance. They also show the complexity in complement receptor-
mediated phagocytosis and raise the question as to whether there
might be selectivity in CRIg-mediated phagocytosis of foreign
pathogens.
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